We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Erlotinib Improved QOL in Advanced NSCLC, National Cancer Institute of Canada Trial BR.21 Finds

Sep 1, 2005
Volume: 
14
Issue: 
8
  • Lung Cancer, Lung Cancer

TORONTO, Canada-Erlotinib
(Tarceva) not only extended survival
in patients with advanced non-smallcell
lung cancer (NSCLC) but it also
improved their quality of life (QOL),
according to data from BR.21, a double-
blind randomized placebo-controlled
trial in 731 patients. Pain, cough,
and dyspnea got worse at a slower rate
among patients who took erlotinib
than among those who took placebo
on the trial, which was conducted by
the National Cancer Institute of Canada
(NCIC).

The primary findings of BR.21, reported
last year, showed that erlotinib
significantly improved median overall
survival time and 1-year survival, compared
with placebo, in patients with
previously treated stage IIIb or IV
NSCLC. The QOL data from BR.21
were reported by Andrea Bezjak, MD,
who led the QOL analysis (abstract
7018). Dr. Bezjak is associate professor
in the departments of radiation oncology
and health policy, management
and evaluation at the University of
Toronto, and is a staff radiation oncologist
at Princess Margaret Hospital,
Toronto.

"Patients on erlotinib had slower
deterioration of their disease-related
symptoms and quality of life improved
in more patients on the erlotinib arm
than on the placebo arm," Dr. Bezjak
said. "These differences were clinically
as well as statistically significant."

To collect the data, Dr. Bezjak and
her colleagues used the QOL core questionnaire
and lung cancer module of
the European Organization for Research
and Treatment of Cancer
(EORTC); the questionnaire was administered
monthly. Compliance wasexcellent, Dr. Bezjak noted, with 85%
of patients completing questionnaires
in the first year.

The results showed that the median
time to deterioration of cough was
4.9 months for patients on the erlo-tinib arm of the study vs 3.7 months
for those on the placebo arm. For dyspnea,
the median time to deterioration
was 4.7 months vs 2.9 months;
and for pain, it was 2.8 months vs 1.9
months, respectively.

The researchers also analyzed global
QOL by determining how many
patients had an improvement of at
least 10 points during the study. Theyfound that 35% of the patients on
erlotinib fell into this category vs 26%
of those on placebo. The favorable
impact of erlotinib included less fatigue,
which is usually difficult to
achieve, Dr. Bezjak noted.

Erlotinib is one of several agents
that have been tested as second-line
therapy in "this burgeoning population"
of patients with advanced
NSCLC, said discussant Vincent Miller,
MD, associate attending physician
in the Thoracic Oncology Service at
Memorial Sloan-Kettering Cancer
Center, New York. Dr. Miller reviewed
trials with docetaxel (Taxotere), topotecan
(Hycamtin), pemetrexed (Alimta),
and erlotinib. He concluded
that docetaxel, pemetrexed, and erlotinib
are all reasonable choices as second-
line therapy but further study is
needed, including trials of combination
therapies. In addition, he said,
"erlotinib, though having a favorable
quality-of-life profile, has not yet been
compared with a cytotoxic agent in
this population, and I do think that
would be a very appropriate study to
undertake."

Related Articles

  • Epacadostat/Durvalumab Combo Well Tolerated in Solid Tumor Trial
  • Antibiotics Reduced Efficacy of Checkpoint Inhibitors in RCC, NSCLC
  • Systemic Treatment Options for Brain Metastases from Non–Small-Cell Lung Cancer
  • New Option in NSCLC With IL-15 Agonist Plus Immune Checkpoint Inhibition
  • Durable Responses, Longer Survival Seen in NSCLC With Nivolumab at 5 Years

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.